Joseph R Brady
Overview
Explore the profile of Joseph R Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Dalvie N, Brady J, Naranjo C, Lorgeree T, Rodriguez-Aponte S, et al.
Biotechnol Bioeng
. 2024 Nov;
122(2):361-372.
PMID: 39543843
Monoclonal antibodies (mAbs) are a major class of biopharmaceuticals manufactured by well-established processes using Chinese Hamster Ovary (CHO) cells. Next-generation biomanufacturing using alternative hosts like Komagataella phaffii could improve the...
2.
Dalvie N, Rodriguez-Aponte S, Hartwell B, Tostanoski L, Biedermann A, Crowell L, et al.
Proc Natl Acad Sci U S A
. 2021 Sep;
118(38).
PMID: 34493582
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs). Recently approved vaccines provide needed interventions, albeit at prices that may limit their global...
3.
Dalvie N, Brady J, Crowell L, Tracey M, Biedermann A, Kaur K, et al.
Microb Cell Fact
. 2021 May;
20(1):94.
PMID: 33933073
Background: Vaccines comprising recombinant subunit proteins are well-suited to low-cost and high-volume production for global use. The design of manufacturing processes to produce subunit vaccines depends, however, on the inherent...
4.
5.
Dalvie N, Rodriguez-Aponte S, Hartwell B, Tostanoski L, Biedermann A, Crowell L, et al.
bioRxiv
. 2021 Mar;
PMID: 33688647
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs). Recently approved vaccines provide needed interventions, albeit at prices that may limit their global...
6.
Lu A, Maloney A, Dalvie N, Brady J, Love K, Love J, et al.
Biotechnol Bioeng
. 2021 Feb;
118(5):1832-1839.
PMID: 33527350
Development of continuous biopharmaceutical manufacturing processes is an area of active research. This study considers the long-term transgene copy number stability of Pichia pastoris in continuous bioreactors. We propose a...
7.
Sawant N, Kaur K, Holland D, Hickey J, Agarwal S, Brady J, et al.
J Pharm Sci
. 2020 Dec;
110(3):1042-1053.
PMID: 33285182
A two-step developability assessment workflow is described to screen variants of recombinant protein antigens under various formulation conditions to rapidly identify stable, aluminum-adjuvanted, multi-dose vaccine candidates. For proof-of-concept, a series...
8.
Kaur K, Xiong J, Sawant N, Agarwal S, Hickey J, Holland D, et al.
J Pharm Sci
. 2020 Dec;
110(3):1054-1066.
PMID: 33278412
In a companion paper, a two-step developability assessment is presented to rapidly evaluate low-cost formulations (multi-dose, aluminum-adjuvanted) for new subunit vaccine candidates. As a case study, a non-replicating rotavirus (NRRV)...
9.
Brady J, Tan M, Whittaker C, Colant N, Dalvie N, Love K, et al.
ACS Synth Biol
. 2020 Aug;
9(9):2515-2524.
PMID: 32786350
Constructing efficient cellular factories often requires integration of heterologous pathways for synthesis of novel compounds and improved cellular productivity. Few genomic sites are routinely used, however, for efficient integration and...
10.
Dalvie N, Leal J, Whittaker C, Yang Y, Brady J, Love K, et al.
ACS Synth Biol
. 2019 Dec;
9(1):26-35.
PMID: 31825599
There is growing interest in the use of nonmodel microorganisms as hosts for biopharmaceutical manufacturing. These hosts require genomic engineering to meet clinically relevant product qualities and titers, but the...